The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,332.00
Bid: 12,344.00
Ask: 12,346.00
Change: 68.00 (0.55%)
Spread: 2.00 (0.016%)
Open: 12,268.00
High: 12,388.00
Low: 12,256.00
Prev. Close: 12,264.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-WHO says vaccine makers working non-stop to plug supply gap, urges patience

Thu, 28th Jan 2021 10:23

(Adds quote from WHO Europe vaccination expert)

* WHO urges solidarity amid vaccine rollout 'teething
problems'

* EU, Britain clash over delays in promised vaccine supply

* WHO's Kluge hopes 'extra future production' eases delays

* Russian vaccine data bound for Geneva -WHO Europe boss

By Stephanie Nebehay and John Miller

GENEVA, Jan 28 (Reuters) - The World Health Organization's
Europe director Hans Kluge said on Thursday vaccine
manufacturers were working non-stop to plug shortfalls in
supplies to countries struggling to contain the COVID-19
pandemic and urged them not to jostle for deliveries.

"Solidarity does not necessarily mean that each country in
the world starts (vaccinating) at exactly the same moment ...
The good understanding is that no one is safe before everyone is
safe," Kluge told an online news briefing.

Asked about delays in expediting Pfizer and
AstraZeneca vaccines to patients across the 27-nation
European Union, Kluge and a WHO-Europe vaccination expert,
Siddhartha Datta, appealed to governments and manufacturers to
cooperate in addressing "teething problems" in the rollout.

"The reality is there is a shortage of vaccines...(But) we
don't doubt that manufacturers and producers are working 24-7 to
bridge the gaps and we're confident the delays we are seeing now
are going to be made up by extra production in the future,"
Kluge said.

The WHO reiterated that vaccines should be shared equitably,
between poor and rich nations, to help end the pandemic with
Datta stressing COVID-19 vaccines were "a global public good".

As Kluge and Datta spoke, Europe's fight to secure COVID-19
vaccine supplies escalated as Britain demanded that it receive
all the shots it paid for after the EU asked AstraZeneca to
divert supplies from the UK.

The EU, whose members are far behind Israel, the United
Kingdom and the United States in dispensing vaccines, is
scrambling to obtain shots just as the West's biggest drugmakers
slow deliveries to the bloc due to production problems.

"We need to be patient, it will take time to vaccinate,"
Kluge said, adding that a total of 35 countries in Europe had
launched vaccinations with 25 million does administered so far.

PANDEMIC PARADOX

"This paradox, where communities sense an end is in sight
with the vaccine but, at the same time, are called to adhere to
restrictive measures in the face of a new threat, is causing
tension, angst, fatigue, and confusion. This is completely
understandable in these circumstances."

Kluge said continued high rates of transmission and emerging
variants of the virus made it urgent to vaccinate priority
groups, but acknowledged the rate of vaccine production and
distribution was not yet up to expectations.

He reiterated the WHO's stance that "vaccination passports"
- proof that somebody has been inoculated - will be important to
monitor inoculation coverage and efficacy of shots, but should
not be used as a litmus test for allowing people to travel.

Asked about WHO's scrutiny of Russia's Sputnik V vaccine,
Kluge said he had spoken with Moscow's ambassador on Wednesday
and that he could confirm that data needed by WHO scientists to
review the shot was en route to Geneva where the WHO is based.

The Russian vaccine is being distributed in Europe including
EU member state Hungary as well as elsewhere in the world, even
though the European Medicines Agency is not currently reviewing
it for approval.
(Reporting by Stephanie Nebehay and John Miller
Editing by Mark Heinrich)

More News
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.